Protagonist Therapeutics

PTGX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$103.78

+0.11% today

52W: $39.60 – $107.84

52W Low: $39.60 Position: 94.1% 52W High: $107.84

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

143.91x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$6.6B

Market Capitalization

Revenue Growth

-95.6%

YoY Revenue Growth

Profit Margin

-282.83%

Net profit margin

ROE

-20.18%

Return on Equity

Beta

2.11

Market sensitivity

Short Interest

15.07%

% of float sold short

Avg. Volume

812,573

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

12 analysts

Avg. Price Target

$112.42

+8.32% upside

Target Range

$97.00 – $125.00

About the Company

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 132 Exchange: NGM